Royal Bank Of Canada Genprex, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.19 - $0.37 $81 - $158	429 Added 14.17%	3,456 $0
Q3 2023 Nov 14, 2023	SELL	$0.37 - $1.04 $46 - $132	-127 Reduced 4.03%	3,027 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.74 - $1.1 $407 - $606	-551 Reduced 14.87%	3,154 $2,000
Q1 2023 May 15, 2023	BUY	$0.76 - $1.78 $915 - $2,144	1,205 Added 48.2%	3,705 $3,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $906 - $53,272	-906 Reduced 26.6%	2,500 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $508 - $22,330	385 Added 12.74%	3,406 $5,000
Q1 2022 May 16, 2022	BUY	$1.82 - $3.5 $948 - $1,823	521 Added 20.84%	3,021 $7,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $263,439 - $341,759	-101,714 Reduced 97.6%	2,500 $7,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.87 $324,105 - $507,522	104,214 New	104,214 $349,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.